Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Repligen Corp

+ Add to Watchlist

RGEN:US

24.9300 USD 0.5400 2.12%

As of 11:47:53 ET on 03/03/2015.

Company Profile for Repligen Corp (RGEN)

Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.

Contact Information

Repligen Corp

41 Seyon Street
Building 1 Suite 100
Waltham, MA 02453
United States
Phone: 1-781-250-0111
Fax: 1-781-250-0115

Key Executives for Repligen Corp (RGEN)

Walter C HerlihyPresident/CEO/TreasurerTony J HuntChief Operating Officer
Jon K SnodgresChief Financial OfficerJames R RuscheSenior VP:Research & Dev
Howard BenjaminVP:Business DevelopmentSondra S NewmanDirector:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil